<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085578</url>
  </required_header>
  <id_info>
    <org_study_id>CG400549-1-01</org_study_id>
    <nct_id>NCT01085578</nct_id>
  </id_info>
  <brief_title>CG400549 Single Ascending Dose Study</brief_title>
  <official_title>Evaluation of Safety,Tolerability and Pharmacokinetic Characteristics of CG400549 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CrystalGenomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CrystalGenomics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of CG400549 in Healthy&#xD;
      Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 1, 2-part study consisting of a randomized, double-blind,&#xD;
      placebo-controlled,single ascending dose (SAD) part (in 2 alternating panels) and a&#xD;
      1-sequence food effect (FE) part. In the SAD part, 2 cohorts of 6 healthy male subjects each&#xD;
      received a single oral dose of CG400549 or placebo in 3 periods, randomized such that each&#xD;
      subject received active treatment twice and placebo once (in each period, 4 subjects received&#xD;
      active drug and 2 received placebo). In the FE part, 1 cohort of 6 healthy male subjects&#xD;
      received a single oral dose of CG400549 in the fasted state in Period 1 and a single oral&#xD;
      dose of CG400549 in the fed state in Period 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety</measure>
    <time_frame>1month</time_frame>
    <description>AEs, vital signs, clinical laboratory, 12-lead ECG; physical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>1month</time_frame>
    <description>plasma and urine CG400549 concentrations; PK parameters Cmax, tmax, kel, t1/2,z, AUC0-last, AUC0-inf, %AUC, CL/F, Vd/F, MRT and Ae</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CG400549/placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CG400549/placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CG400549</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG400549/placebo</intervention_name>
    <description>Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1</description>
    <arm_group_label>Cohort1</arm_group_label>
    <other_name>Cohort 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG400549/placebo</intervention_name>
    <description>Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1</description>
    <arm_group_label>Cohort2</arm_group_label>
    <other_name>Cohort 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG400549</intervention_name>
    <description>Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state</description>
    <arm_group_label>Cohort3</arm_group_label>
    <other_name>Cohort 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Sex : male&#xD;
&#xD;
          -  2. Age : 18-55 years, inclusive&#xD;
&#xD;
          -  3. BMI : 19-30 kg/m2&#xD;
&#xD;
          -  4. Ability and willingness to abstain from alcohol, methylxanthine-containing&#xD;
             beverages or food (coffee, tea, cola, chocolate, &quot;powerdrinks&quot;), grapefruit (juice)&#xD;
             and tobacco products from 48 h prior to entry in the clinical research centre until&#xD;
             discharge&#xD;
&#xD;
          -  5. Medical history without major pathology&#xD;
&#xD;
          -  6. Normal blood pressure (systolic 90-140 mmHg; diastolic 60-90 mmHg) and heart rate&#xD;
             (45 90 beats per minute); minor deviations from these criteria could be accepted if&#xD;
             considered to be clinically insignificant by the Medical Investigator&#xD;
&#xD;
          -  7. Computerised (12-lead) ECG recording normal or showing no clinically relevant&#xD;
             deviations as judged by the Medical Investigator&#xD;
&#xD;
          -  8. Male subjects and their female sexual partners must use double-barrier&#xD;
             contraception during the study period and for 90 days after follow-up&#xD;
&#xD;
          -  9. All values for haematology and for clinical chemistry tests of blood and urine&#xD;
             within the normal range or showing no clinically relevant deviations as judged by the&#xD;
             Medical Investigator. In particular, liver enzymes (aspartate aminotransferase [ASAT]&#xD;
             and alanine aminotransferase [ALAT]) must be within the normal range and creatine&#xD;
             phosphokinase (CPK) must be within 2.0 times the normal range.&#xD;
&#xD;
          -  10. Willingness to sign the written Informed Consent Form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Evidence of clinically relevant pathology&#xD;
&#xD;
          -  2. History of bacterial or viral infection requiring treatment with antibiotics or&#xD;
             antivirals within 1 month of study&#xD;
&#xD;
          -  3. Presence or history of esophageal or gastroduodenal ulceration within 1 month&#xD;
             before screening.&#xD;
&#xD;
          -  4. Family history of significant cardiac disease (e.g., sudden cardiac death or&#xD;
             myocardial infarction prior to age 50 in a first-degree relative)&#xD;
&#xD;
          -  5. Mental handicap, relevant cognitive or psychiatric disorders or history of seizures&#xD;
&#xD;
          -  6. History and/or presence of relevant drug and/or food allergies&#xD;
&#xD;
          -  7. Use of concomitant medication, except for acetaminophen (paracetamol), which is&#xD;
             allowed up to 3 days before entrance into the research facility. All other medication&#xD;
             (including over-the-counter medication, health supplements, and herbal remedies such&#xD;
             as St. John's Wort extract) must have been stopped at least 14 days prior to the first&#xD;
             dose. The use of a limited amount of acetaminophen (â‰¤ 2 g/day) is permitted.&#xD;
&#xD;
          -  8. Participation in a drug study within 60 days prior to drug administration.&#xD;
             Participation in more than 3 other drug studies in the 10 months preceding the start&#xD;
             of this study.&#xD;
&#xD;
          -  9. Donation of more than 50 mL of blood (whole blood or blood component) within 60&#xD;
             days prior to drug administration.&#xD;
&#xD;
          -  10. History of alcohol abuse or drug addiction (including soft drugs like cannabis&#xD;
             products)&#xD;
&#xD;
          -  11. Positive screen on drugs of abuse (opiates, methadone, cocaine, amphetamines,&#xD;
             cannabinoids), barbiturates, benzodiazepines, tricyclic antidepressants and alcohol&#xD;
&#xD;
          -  12. Intake of more than 24 units of alcohol per week (one unit of alcohol equals&#xD;
             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)&#xD;
&#xD;
          -  13. Positive screen on hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
          -  14. Positive screen on anti hepatitis C virus (HCV)&#xD;
&#xD;
          -  15. Positive screen on anti human immunodeficiency virus 1 and 2 (HIV 1/2)&#xD;
&#xD;
          -  16. Illness within 5 days prior to drug administration&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seonggu Ro, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CrystalGenomics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International clinical center</name>
      <address>
        <city>Zuidlaren</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2010</study_first_posted>
  <last_update_submitted>February 13, 2013</last_update_submitted>
  <last_update_submitted_qc>February 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy male volunteers</keyword>
  <keyword>fasted and fed state</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

